ArticleCellular and molecular life sciences : CMLS2025
African swine fever virus L11L interferes with antiviral responses by targeting the IRF3 and PKR.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TRIM28 SUMOylates IRF3 in astrocytes to drive neutrophils infiltration and ischemic cerebral injury.Cell death and differentiation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The African Swine Fever Virus (ASFV) is a large, complex DNA virus that infects wild boars and domestic pigs. It causes African Swine Fever (ASF), an intense and often fatal disease with 100% fatality rate. After infection, ASFV employs specific viral proteins to enhance pathogenicity. However, the functions of many of these proteins remain unknown. This study investigated the molecular mechanism by which ASFV L11L evades type I interferon (IFN) pathway and protein kinase R (PKR)-mediated antiviral responses. Interestingly, we found that L11L interacts with interferon regulatory factor 3 (IRF3), specifically with the S396 and S398 amino acids, leading to the inhibition of the phosphorylation of IRF3 by Tank-binding kinase 1 (TBK1). Consequently, this interaction impedes IRF3 dimerization, nuclear translocation and subsequent IFN-β production. Besides, L11L inhibits the dimerization of PKR by targeting its K196 amino acid, preventing the phosphorylation of its substrate, eukaryotic initiation factor-2 (eIF2), to promote viral replication. Altogether, these novel findings conclude that L11L suppresses antiviral immunity and promotes viral replication, implying the identification of a novel target for the advancement of live-attenuated vaccines against ASF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.